verified SJR 0,71 · Q2 • database Scopus / SJR & Web of Science indexed

United Arab Emirates · Bentham Science Publishers

workspace_premium Q2 — Medicine (miscellaneous) lock Subscription

CNS and Neurological Disorders - Drug Targets

CNS and Neurological Disorders - Drug Targets is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology with an H index of 101. It has a price of 2395 €. It has an SJR impact factor of 0,71 and it has a best quartile of Q2. It has an SJR impact factor of 0,71.

ISSN: 1871-5273

Publisher: Bentham Science Publishers

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,71 Q2

H-index 101

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,71

H-index

101

Docs (year)

128

Docs 3y

278

Total refs

14160

Cites 3y

832

Citable 3y

263

Cites/Doc 2y

3.18

Ref/Doc

110.63

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma

Vertical and Horizontal Convergences of Targeting Pathways in Combination Therapy with Baicalin and Jasminoidin for Cerebral Ischemia

CypD: The Key to the Death Door

Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention

Conference Report: 7th Clinical Trials on Alzheimer's Disease Annual Conference, Philadelphia, PA, USA Nov 20-22, 2014

Complex Polyamines: Unique Prion Disaggregating Compounds

Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS

Commentary-2: Repairing the Dopamine System in the Brain with Adult Neurogenesis

Commentary-1 (Research Highlights: USP30 Regulates the Mitophagy-Mediated Neuroprotection in Parkinson's Disease)

Commentary Research Highlights: Untangling Alzheimer Disease Pathology

Cognitive Dysfunction in Depression: Lessons Learned from Animal Models

Cognitive Dysfunction in Depression -Pathophysiology and Novel Targets

SHOW MORE ARTICLES

Childhood Hypertension and Effects on Cognitive Functions: Mechanisms and Future Perspectives

A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility

Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings

Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases

Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System

Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?

Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial

An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-beta

An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy

Alternative Aβ Immunotherapy Approaches for Alzheimers Disease

AD Vaccines: Conclusions and Future Directions

Acknowledgements to the Reviewers:

FAQs

CNS and Neurological Disorders - Drug Targets has an SJR of 0,71 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 2395 EUR.

The acceptance rate recorded for CNS and Neurological Disorders - Drug Targets is 25%.

CNS and Neurological Disorders - Drug Targets

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of CNS and Neurological Disorders - Drug Targets?

What is the APC / publication cost?

What is the acceptance rate?